Skip to main content
. 2012 Oct 24;122(11):4172–4189. doi: 10.1172/JCI63377

Figure 7. Heterotopic expression of osteocalcin from day 8 reduces glucocorticoid-induced changes in body composition.

Figure 7

(A) Body weight as percentage of baseline of EV, wtOCN, and μOCN vector–receiving mice (vector administered via hTVI on day 8) treated with 1.5 mg corticosterone per week or placebo over the 4-week period. (B) Lean body mass of vector-receiving mice treated over the 4-week period. (C) Body fat mass of vector-receiving mice treated over the 4-week period. (D) Fat/lean mass ratio of vector-receiving mice treated over the 4-week period. (E) Serum triglyceride levels of vector-receiving mice treated over the 4-week period. (F) Serum cholesterol levels of vector-receiving mice treated over the 4-week period (“for all” indicates that significance applies to all groups at this time point). *P < 0.05, #P < 0.01, †P < 0.001 compared with respective vector-receiving placebo-treated controls; ‡P < 0.05, **P < 0.01 compared with other corticosterone-treated groups receiving wtOCN and μOCN vectors (repeated-measures ANOVA followed by post-hoc analysis; error bars represent SEM).